DK0907364T3 - Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat - Google Patents

Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat

Info

Publication number
DK0907364T3
DK0907364T3 DK97924103T DK97924103T DK0907364T3 DK 0907364 T3 DK0907364 T3 DK 0907364T3 DK 97924103 T DK97924103 T DK 97924103T DK 97924103 T DK97924103 T DK 97924103T DK 0907364 T3 DK0907364 T3 DK 0907364T3
Authority
DK
Denmark
Prior art keywords
prolonged
pharmaceutical compositions
compositions containing
release pharmaceutical
dibenzothiazepine derivative
Prior art date
Application number
DK97924103T
Other languages
Danish (da)
English (en)
Inventor
Bhavnish Vinod Parikh
Robert Joseph Timko
William Joseph Addicks
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10794541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0907364(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0907364T3 publication Critical patent/DK0907364T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
DK97924103T 1996-05-31 1997-05-27 Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat DK0907364T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9611328.7A GB9611328D0 (en) 1996-05-31 1996-05-31 Pharmaceutical compositions
PCT/GB1997/001432 WO1997045124A1 (en) 1996-05-31 1997-05-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
DK0907364T3 true DK0907364T3 (da) 2002-11-11

Family

ID=10794541

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97924103T DK0907364T3 (da) 1996-05-31 1997-05-27 Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat

Country Status (31)

Country Link
EP (1) EP0907364B1 (ru)
JP (5) JP2000511170A (ru)
CN (3) CN1511532A (ru)
AR (1) AR003662A1 (ru)
AT (1) ATE222105T1 (ru)
AU (1) AU727219B2 (ru)
BR (1) BR9709271A (ru)
CA (1) CA2251944C (ru)
CZ (1) CZ293760B6 (ru)
DE (1) DE69714739T2 (ru)
DK (1) DK0907364T3 (ru)
EG (1) EG24118A (ru)
ES (1) ES2182079T3 (ru)
GB (2) GB9611328D0 (ru)
HR (1) HRP970299B1 (ru)
HU (1) HU225152B1 (ru)
ID (1) ID18352A (ru)
IL (1) IL127222A (ru)
MY (1) MY120120A (ru)
NO (1) NO327801B1 (ru)
NZ (1) NZ332198A (ru)
PL (1) PL189887B1 (ru)
PT (1) PT907364E (ru)
RU (1) RU2201754C2 (ru)
SI (1) SI0907364T1 (ru)
SK (1) SK284131B6 (ru)
TR (1) TR199802483T2 (ru)
TW (1) TW550076B (ru)
UA (1) UA50772C2 (ru)
WO (1) WO1997045124A1 (ru)
ZA (1) ZA974735B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
EP1976487A2 (en) 2006-01-25 2008-10-08 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
PT103884A (pt) * 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
EP1958617B1 (en) 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing quetiapine fumarate
EP2131817A2 (en) 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
PT2262486E (pt) 2008-08-01 2013-03-27 Tovarna Zdravil D D Novo Mesto Krka Composição de quetiapina
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
US20110280938A1 (en) * 2009-01-05 2011-11-17 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
EP2233130A1 (en) * 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
TWI478733B (zh) * 2009-05-13 2015-04-01 Wyeth Llc 突釋藥物釋放組合物
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
CN102218042A (zh) * 2011-05-26 2011-10-19 青岛黄海制药有限责任公司 富马酸喹硫平组合物的缓释片剂及其制备方法
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
CN102406606B (zh) * 2011-11-29 2013-01-23 海南美大制药有限公司 富马酸喹硫平脂质体固体制剂
EP2822541B1 (en) 2012-09-10 2018-08-29 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
US10653699B2 (en) 2015-06-19 2020-05-19 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN106187873B (zh) * 2016-07-25 2019-11-05 宜春学院 一种芳胺基烷基氧类化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4775535A (en) * 1986-04-04 1988-10-04 Hans Lowey Method of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristics
ATE71833T1 (de) * 1986-11-03 1992-02-15 Schering Corp Labetalol tablette mit verzoegerter wirkstoffabgabe.
IE59540B1 (en) * 1987-01-09 1994-03-09 Elan Corp Sustained release capsule or tablet formulation
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US4983398A (en) * 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
IT1256651B (it) * 1992-12-11 1995-12-12 Giancarlo Santus Composizione farmaceutica a rilascio controllato in sospensione liquida
JP3116970B2 (ja) * 1991-06-12 2000-12-11 三菱東京製薬株式会社 ペミロラストカリウムの徐放性製剤
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US5919491A (en) * 1994-05-13 1999-07-06 Smithkline Beecham Corporation Method and composition for increasing calcium uptake

Also Published As

Publication number Publication date
ES2182079T3 (es) 2003-03-01
CN1142780C (zh) 2004-03-24
ID18352A (id) 1998-04-02
CN101006985A (zh) 2007-08-01
DE69714739D1 (de) 2002-09-19
PT907364E (pt) 2002-12-31
AU727219B2 (en) 2000-12-07
AR003662A1 (es) 1998-09-09
CZ388098A3 (cs) 1999-02-17
HRP970299A2 (en) 1998-04-30
JP2006152006A (ja) 2006-06-15
SK163998A3 (en) 1999-05-07
HRP970299B1 (en) 2001-12-31
CZ293760B6 (cs) 2004-07-14
NO985539L (no) 1998-11-27
IL127222A0 (en) 2000-06-01
BR9709271A (pt) 1999-08-10
NO985539D0 (no) 1998-11-27
JP2007119495A (ja) 2007-05-17
ATE222105T1 (de) 2002-08-15
EP0907364B1 (en) 2002-08-14
HUP9902194A3 (en) 2000-03-28
SK284131B6 (sk) 2004-09-08
PL330223A1 (en) 1999-05-10
SI0907364T1 (en) 2003-02-28
MY120120A (en) 2005-09-30
CN1511532A (zh) 2004-07-14
TW550076B (en) 2003-09-01
RU2201754C2 (ru) 2003-04-10
HU225152B1 (en) 2006-07-28
CA2251944C (en) 2007-04-10
NZ332198A (en) 2000-05-26
JP5888549B2 (ja) 2016-03-22
HUP9902194A2 (hu) 2000-02-28
CN1219879A (zh) 1999-06-16
EG24118A (en) 2008-07-06
AU2967597A (en) 1998-01-05
EP0907364A1 (en) 1999-04-14
IL127222A (en) 2001-03-19
JP2012031206A (ja) 2012-02-16
NO327801B1 (no) 2009-09-28
GB9709761D0 (en) 1997-07-09
JP2014167026A (ja) 2014-09-11
JP2000511170A (ja) 2000-08-29
DE69714739T2 (de) 2003-05-15
TR199802483T2 (xx) 1999-02-22
GB9611328D0 (en) 1996-08-07
WO1997045124A1 (en) 1997-12-04
PL189887B1 (pl) 2005-10-31
ZA974735B (en) 1997-12-01
CA2251944A1 (en) 1997-12-04
UA50772C2 (ru) 2002-11-15

Similar Documents

Publication Publication Date Title
DK0907364T3 (da) Farmaceutiske præparater med langvarig frigivelse indeholdende et dibenzothiazepinderivat
EE04294B1 (et) Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
BR9602759A (pt) Composição farmacêutica oral organoleticamente aceitável
FI955311A0 (fi) Farmaseuttinen koostumuspohja
BR9602758A (pt) Composição farmacêutica oral organoleticamente aceitável
DE69822172D1 (de) Levosimendanhaltige oral anzuwendende arzneizusammensetzungen
HU9800573D0 (en) Rapamycin formulations for oral administration
FI944534A (fi) Rapamysiinikoostumuksia oraalisesti annettaviksi
EE9900545A (et) Farmatseutiline kompositsioon
ID16781A (id) Formulasi-formulasi farmasi
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
ID29294A (id) Komposisi farmasi
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
NO996044L (no) Rapamycinformuleringer for oral administrasjon
ITMI941169A0 (it) Formulazioni farmaceutiche
PT941100E (pt) Composicoes farmaceuticas
ID25857A (id) Komposisi farmasi
BR9707827A (pt) Formulações farmacêuticas de liberação prolongada contendo a mizolastina
BR9710568A (pt) Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2
ITMI962628A0 (it) Composizione farmaceutica
ID23531A (id) Komposisi farmasi
ID17133A (id) Komposisi farmasi
SE9604299D0 (sv) Pharmaceutical composition
SE9601854D0 (sv) Farmaceutisk komposition
SE9402925D0 (sv) Novel oral pharmaceutical composition